Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergic rhinitis indication may lead to diagnosis errors -- allergy cmte. member.

This article was originally published in The Tan Sheet

Executive Summary

NASALCROM BROAD RHINITIS OTC INDICATION PRESENTS "RISK" OF EXTENDED USE by consumers for whom the medication would be "ineffective," James Li, MD/PhD, Mayo Clinic, said Oct. 10 at a meeting of FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees in Bethesda, Md. held to discuss McNeil's proposed Rx-to-OTC switch of cromolyn sodium nasal spray. The anti-allergy nasal treatment was recommended for prevention and treatment of allergic rhinitis, covering both seasonal and perennial indications.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel